Founded in 2013 and headquartered in Tallahassee, Florida, Insilicom is dedicated to advancing cancer research through biomarker discovery. The company's core mission is to leverage next-generation sequencing data analysis to uncover critical biomarkers for cancer research. Insilicom offers products like BioKDE, a deep learning-powered biomedical knowledge discovery engine, and iPV, an AI-powered pharmacovigilance platform. These tools enhance literature search, knowledge discovery, and drug adverse event monitoring, primarily focusing on the biomedical research and pharmaceutical markets.

Insilicom has been supported by notable investors and collaborators in the biotech and AI sectors. The company has achieved significant milestones, including outperforming traditional search engines in biomedical literature search and visualization. By providing powerful and versatile tools for relation search and adverse event monitoring, Insilicom has made a substantial impact on the efficiency and effectiveness of cancer research and pharmacovigilance, positioning itself as a leader in the integration of AI with biomedical data analysis.